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Conclusions: A high proportion of patients experienced a 
local relapse alone following treatment suggesting that 
radiotherapy alone without chemo-sensitisation does not 
achieve high rates of local control. The use of alternate 
approaches such as brachytherapy to provide a local boost 
may have merit and warrants further investigation. Despite 
this, there are some patients who achieve respectable 
relapse free survival and overall survival, but others where a 
palliative approach might be more appropriate. Further work 
needs to be done to understand the factors influencing 
patient outcomes following definitive radiotherapy. Further 
refinement in patient selection will follow with better 
understanding of radio-genomic profiling. 
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Purpose/Objective: To evaluate toxicity and outcomes of 
patients with anal canal cancer treated with 
hypofractionated radiotherapy schedule and a Simultaneous 
Integrated Boost with Helical Tomotherapy. 
Materials and Methods: From March 2009 to March 2014 41 
patients were treated with simultaneous integrated boost- 
intensity modulated radiotherapy and concurrent 
chemotherapy for anal canal squamous carcinoma. Two 
clinical target volumes were delineated, radiotherapy dose 
was adapted to disease stage: 50.6 Gy and 41.4 Gy in 23 
fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractions in T2N0 
and 55 and 45 Gy in 25 fractions in all patients with N+ 
and/or ≥T3, prescribed to Planning Target Volume 1 and 
Planning Target Volume 2 respectively. The most common 
chemotherapy regimen was 5-fluorouracil and mitomycin 
based. 
Results: The median age was 63 years (range 32-84). 5, 10, 
11 and 14 patients were respectively in stage I, II, IIIA and 
IIIB. A complete response was achieved in 34/38 (89.4%) 
patients evaluable for outcomes, one partial response in 1 
patient, inoperable persistence of disease was observed in 1 
patient and progressive disease in 2 patients (local and 
metastatic respectively). Acute grade 3 skin and grade 3 
gastrointestinal toxicity was reported in 5% and 7.3% of 
patients, respectively; treatment breaks due to toxicity were 
required in 7.3% of patients. With a median follow up of 20 
months, the 2-year overall survival and disease free survival 
were 90.4% and 92.3%. 
Conclusions: In our experience, intensity modulated 
radiotherapy with simultaneous integrated boost is feasible 
and allows the obtainment of excellent results data in terms 
of overall survival, local control and toxicity without several 
breaks due to acute toxicity. 
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Purpose/Objective: The purpose of this study was to 
retrospectively assess the clinical outcome in anal cancer 
patients treated with curative intent chemo-radiotherapy in 
terms of local control (LC), distant metastases-free survival 
(DMFS) and overall survival (OS). 
Materials and Methods: From January 2002 to December 
2012, 125 patients were treated for anal carcinoma in our 
Department of Radiotherapy in Policlinico S. Orsola-Malpighi, 
Bologna. The treatment consisted of 3DCRT on the pelvis 
(median dose: 45 Gy /1.8 Gy) with concurrent chemotherapy 
(5-fluorouracil and Mitomycin-C). After a clinical response 
evaluation patients received a boost 2-3 weeks after the end 
of the 3D-CRT by either pulsed dose rate brachytherapy (80% 
of the patients, mean dose: 18.5 Gy) or without any 
interruption by external beam radiotherapy (20%, mean dose 
16.4 Gy) in patients with controindications to brachytherapy. 
Exclusion criteria for brachytherapy were: initial diffusion of 
cancer > 2/3 of circumpherence of anal canal, initial 
extended diffusion at the perianal skin, presence of a 
residual >5 cm in longitudinal or >1,5 cm in deepth after 3D-
CRT (first course) and the clinical controindication for 
anesthesia. LC, DMFS and OS were analyzed using Kaplan-
Meier method. A comparison of the survival curves was 
performed using long rank test (univariate analysis). 
Results: Males were 31 (25%), females 94 (75%). Median age 
was 61 years (range 37-94 years), elderly patients (over 65 
years-old) were 53 (42%). Tumor stage was T1 in 18 patients 
(14%), T2 in 45 patients (36%), T3 in 41 patients (33%), T4 in 
21 patients (17%). Nodal stage was N0 in 71 patients (57%), 
N1 in 29 (23%), N2 in 13 (10%). The histology was squamous-
cell carcinoma (78%) and non squamous-cell carcinoma (22%). 
HIV+ e HPV+ patients were 7 (6%) and 2 (2%), respectively. 
Median follow-up was 43 months (range: -132 months). The 5-
year LC rate was 83%. No significant association between 5-
year LC and clinicopathologic factors (age, T stage, N stage, 
histology, and HIV status) was recorded (p: NS). The 5-year 
DMFS was 93%. N stage was significantly correlated with 5-
year metastasis free survival (p<0.05). The 5-year OS was 




Conclusions: Our results confirmed that radiochemotherapy 
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provides an excellent LC. However, despite good local 
control we observed a crude distant metastasis rate of 25% in 
N2 disease, suggesting a need for novel chemotherapeutic 
approaches to improve systemic control in these patients. OS 
was significantly influenced by T staging (p=0.035), 
suggesting the need for dose escalation in patients with 
higher T-stage (cT3-T4). Therefore, further studies are 
warranted to evaluate if dose escalation to both gross tumor 
and areas of potential nodal spread can improve LC and OS. 
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Purpose/Objective: Intra luminal brachytherapy (ILBT) is 
utilised for oesophageal cancer as a palliative treatment with 
the aim to improve and maintain patients’ swallowing 
function and delaying or avoiding the need for an 
endoluminal oesophageal stent. It is utilised as a boost 
treatment following external beam radiotherapy in patients’ 
deemed unsuitable for definitive chemoradiation or high dose 
external beam treatments; or as salvage treatment for those 
with relapsed disease more than 6 months from external 
beam treatment.Treatment was delivered either as a single 
8Gy dose to the PTV or 14-16 Gy in 2 fractions a maximum of 
1 week apart. In this retrospective analysis, we evaluate the 
outcomes of patients treated with ILBT in West Yorkshire 
over a 4 year period.  
Materials and Methods: Information collected from entries in 
the Leeds oesophageal brachytherapy database and patient 
pathway manager (clinical data software). Data on basic 
patient/tumour demographics, date of treatment, 
dose/fractionation schedule of treatment, brachytherapy 
dosimetric data, toxicity profile, swallowing assessment 
before and after treatment and date of subsequent 
oesophageal stent (if needed) was reviewed.  
All ILBT treatments were 3D CT conformal planned  
Results: A total of 33 patients have been treated between 
April 2010 and August 2014. The median performance status 
was one. 21patients (64%) patients had a single treatment. 
Most treatments (76 %) were given as boost following 30Gy in 
10 fractions of external beam radiotherapy. 27% of patients 
required subsequent oesophageal stent insertion for 
palliation of critical dysphagia. The median overall survival 
was 211 days whilst the median stent free survival was 204 
days. 6% of patients had documented grade 3 RTOG toxicity, 
related to dysphagia. There were no treatment related 
bleeding or perforation events. The median PTV volume was 
38.3cm3 with the median maximum diameter for each PTV 
38.0mm. Mean PTV V100 was 81.9%(+/-15.2%, 1SD), and V200 
of 38.1%(+/- 13.2%, 1SD). Mean PTV D90 was 6.4Gy(+/- 
1.5Gy, 1SD) and Mean GTV D90 was 7.2Gy(+/- 1.3%, 1SD) for 
each fraction. The spinal cord mean D2cc (maximum dose for 
2cc volume of spinal cord) was 1.1Gy(+/- 0.5Gy, 1SD) whilst 
the mean D0.1cc was 1. 5Gy(+/- 0.6Gy, 1Sd). 
Conclusions: Intra luminal oesophageal brachytherapy is a 
safe and effective method of delivering palliative 
radiotherapy for patients with oesophageal cancer where 
other radical treatments are deemed inappropriate. It is well 
tolerated and can delay or eliminate the need for 
oesophageal stents for symptomatic dysphagia. Further study 
in to the role of using sequential ILBT with removable stents 
to maintain swallowing function is required.  
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Purpose/Objective: Standard treatment for locally advanced 
rectal cancer is neoadjuvant fluoropyrimidine-based 
chemoradiotherapy (CRT) followed by total mesorectal 
excision. Research has been focused on intensifying 
neoadjuvant treatment. This systematic review evaluated 
Phase II treatment intensification trials. 
Materials and Methods: A systematic search of the PubMed, 
EMBASE, MEDLINE and the Cochrane Library databases was 
performed from January 2004 to September 2014 for all 
published Phase II trials of neoadjuvant treatment 
intensification in locally advanced rectal cancer. Eighty-one 
eligible Phase II trials were identified from 474 articles. For 
each trial, clinical, methodological and statistical 
components were assessed. 
Results: Ninety-one experimental arms from 81 trials were 
identified. Median number of patients recruited per trial was 
50 (range: 8–279) over a median recruitment period of 26 
months (range: 4–108). Eighty-three arms studied CRT 
intensification: 36(36.6%) additional cytotoxic, 10(11.0%) 
additional biological agent, 3(3.3%) additional radiosensitiser, 
16(17.6%) radiotherapy dose intensification, and 18(19.8%) a 
combination of agents. Neoadjuvant chemotherapy was 
added in 22 experimental arms (14 arms alongside CRT 
intensification): 7(7.7%) additional cytotoxic, 1(1.1%) 
additional biological agent and 6(6.6%) a combination of 
agents. 
Only nine trials were randomised of which five had a 
standard control arm. Twenty studies did not report a 
sample size calculation and only 44(54.3%) studies stated 
their statistical trial design. Fifteen differently defined 
primary endpoints were stated in 73 studies. Seventy-six 
trials recruited both AJCC stage II and III disease. MRI local 
staging was mandated in 35 trials while the circumferential 
resection margin was assessed in only 10 trials. Only 31 of the 
81 studies were rated to have a good overall statistical design 
and compliance. No meta-analysis could be performed due to 
trial heterogeneity. 
Conclusions: The very small number of randomised phase II 
trials, the lack of agreement regarding useful primary end 
points and the poor clinical trial design quality are major 
concerns. These factors are likely to be a major contributor 
